| A quantitative comparison of antibodies to programmed cell death 1 ligand 1 P Gaule, JW Smithy, M Toki, J Rehman, F Patell-Socha, D Cougot, ... JAMA Oncology 3 (2), 256-259, 2017 | 202 | 2017 |
| Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma DB Johnson, J Bordeaux, JY Kim, C Vaupel, DL Rimm, TH Ho, ... Clinical Cancer Research 24 (21), 5250-5260, 2018 | 142 | 2018 |
| High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling MI Toki, CR Merritt, PF Wong, JW Smithy, HM Kluger, KN Syrigos, GT Ong, ... Clinical Cancer Research 25 (18), 5503-5512, 2019 | 139 | 2019 |
| Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma PF Wong, W Wei, JW Smithy, B Acs, MI Toki, KRM Blenman, D Zelterman, ... Clinical Cancer Research 25 (8), 2442-2449, 2019 | 123 | 2019 |
| Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations MI Toki, N Mani, JW Smithy, Y Liu, M Altan, B Wasserman, R Tuktamyshov, ... Journal of Thoracic Oncology 13 (12), 1884-1896, 2018 | 88 | 2018 |
| Multiplex quantitative analysis of cancer-associated fibroblasts and immunotherapy outcome in metastatic melanoma PF Wong, W Wei, S Gupta, JW Smithy, D Zelterman, HM Kluger, DL Rimm Journal for immunotherapy of cancer 7, 1-10, 2019 | 62 | 2019 |
| Adaptive dosing of nivolumab+ ipilimumab immunotherapy based upon early, interim radiographic assessment in advanced melanoma (the ADAPT-IT study) MA Postow, DA Goldman, AN Shoushtari, A Betof Warner, MK Callahan, ... Journal of Clinical Oncology 40 (10), 1059-1067, 2022 | 41 | 2022 |
| Nuclear IRF-1 expression as a mechanism to assess “Capability” to express PD-L1 and response to PD-1 therapy in metastatic melanoma JW Smithy, LM Moore, V Pelekanou, J Rehman, P Gaule, PF Wong, ... Journal for immunotherapy of cancer 5, 1-9, 2017 | 34 | 2017 |
| Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma S Gupta, L McCann, YGY Chan, EW Lai, W Wei, PF Wong, JW Smithy, ... Journal for ImmunoTherapy of Cancer 7, 1-8, 2019 | 19 | 2019 |
| Publication of Pivotal Efficacy Trials for Novel Therapeutic Agents Approved Between 2005 and 2011: A Cross-sectional Study JW Smithy, NS Downing, JS Ross JAMA Internal Medicine 174 (9), 1518-1520, 2014 | 18 | 2014 |
| Facts and hopes in prediction, diagnosis, and treatment of immune-related adverse events JW Smithy, DM Faleck, MA Postow Clinical Cancer Research 28 (7), 1250-1257, 2022 | 16 | 2022 |
| Pancreas cancer: Therapeutic trials in metastatic disease JW Smithy, EM O'Reilly Journal of Surgical Oncology 123 (6), 1475-1488, 2021 | 16 | 2021 |
| Factors determining long-term antitumor responses to immune checkpoint blockade therapy in melanoma K Loo, JW Smithy, MA Postow, A Betof Warner Frontiers in Immunology 12, 810388, 2022 | 13 | 2022 |
| Checkpoint blockade in melanoma patients with underlying chronic lymphocytic leukemia JW Smithy, MJ Pianko, C Maher, MA Postow, AN Shoushtari, P Momtaz, ... Journal of Immunotherapy 44 (1), 9-15, 2021 | 9 | 2021 |
| Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough? JW Smithy, AN Shoushtari Cancer Discovery 12 (3), 599-601, 2022 | 7 | 2022 |
| Quantitative assessment of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma PF Wong, JW Smithy, KR Blenman, HM Kluger, DL Rimm Cancer Research 78 (13_Supplement), 3638-3638, 2018 | 7 | 2018 |
| Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations. M Toki, N Mani, JW Smithy, Y Liu, M Altan, B Wasserman, R Tuktamyshov, ... Journal of Clinical Oncology 35 (15_suppl), 9076-9076, 2017 | 7 | 2017 |
| Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM). DB Johnson, J Bordeaux, JY Kim, C Vaupel, DL Rimm, TH Ho, ... Journal of Clinical Oncology 35 (15_suppl), 9517-9517, 2017 | 5* | 2017 |
| Ensuring equity in the era of HLA-restricted cancer therapeutics JW Smithy, A Blouin, LC Diamond, M Postow Journal for Immunotherapy of Cancer 10 (11), 2022 | 4 | 2022 |
| Adjuvant checkpoint blockade following complete local therapy for melanoma metastases JW Smithy, MA Postow The Lancet 400 (10358), 1082-1083, 2022 | 3 | 2022 |
